Pro-Pharmaceuticals, Inc.'s Begins Process Of New Drug Application Submission With The FDA For Co-administration Of DAVANAT(R) With 5-FU In Cancer Patients

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds, today announced it has begun the process of submitting a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) for co-administration of DAVANAT® with 5-Fluorouracil (5-FU) for treatment in cancer patients.